Anavex Life Sciences Corp (AVXL)

[frrol]

Yes. The Excellence issue is the fault of the CRO who, like our AD trial CRO, was not on top of its trial sites. Our (internal) clinical director failed twice in not being on top of them, and Missling has responsibility for him/her, but clinical operations is not Missling's sole responsibility. Excellence was a small trial, and it should not have taken nearly this long for TLR, but if we get results "soon", it's fine. This is not the company's first fumble.

Aside from the Excellence TLR, we will likely get more AD regulatory news in 1Q '24 (FDA, TGA, maybe Japan). China would be huge, but I've never heard Missling mention that. Hopefully we'll finally get the other long-promised trials underway. The company has a big backlog of unmet milestones. Let's see.